EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genome-Scale CRISPR Screens Reveal DNA Repair Dependencies That Sensitize Hepatocellular Carcinoma to Oxaliplatin

Hanyue Ouyang, Diyun Huang iD, Dongsheng Wen, Lichang Huang, Zichao Wu, Zhicheng Lai, Minke He, Wenchao Wu iD, Ming Shi

Cancers · 24.04.2026 · 18 (9) · 1360

DOI: 10.3390/cancers18091360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 24.04.2026. Verfasst von Hanyue Ouyang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Most patients with hepatocellular carcinoma (HCC) present with advanced disease and have limited systemic treatment options. Oxaliplatin shows clinical activity in HCC but its effectiveness is frequently curtailed by intrinsic and acquired resistance. We sought to systematically identify genetic vulnerabilities that increase oxaliplatin sensitivity in HCC.

Methods

Genome-scale negative-selection CRISPR–Cas9 screens were conducted in two genetically distinct HCC cell lines (Hep3B and MHCC-97H) under low-dose oxaliplatin to discover conserved determinants of sensitivity. Selected DNA damage response (DDR) hits were validated. An oxaliplatin-resistant MHCC-97H subline was generated for transcriptomic profiling to characterize resistance-associated programs. Screen results were integrated with TCGA-LIHC expression and survival data to evaluate clinical relevance. Additionally, we analyzed bulk RNA-seq data from biopsy specimens collected from 36 HCC patients prior to initiation of hepatic arterial infusion chemotherapy (HAIC), comparing expression levels of the DDR genes between patients with objective response and non-responders.

Results

Screens in both cell lines converged on DDR pathways, particularly nucleotide excision repair (NER) and the Fanconi anemia/interstrand crosslink repair network; shared sensitizers included ERCC4 (XPF), FANCE and SLX4. Validation experiments showed that disruption of representative DDR factors (POLH and XPA) synergistically increased oxaliplatin efficacy at concentrations as low as 0.5 μM. Transcriptomic analysis of the resistant MHCC-97H subline revealed coordinated upregulation of DNA repair programs, G2/M checkpoint and E2F target signatures, and epithelial–mesenchymal transition features. Integration with TCGA-LIHC data demonstrated frequent overexpression of many screen-identified DDR genes in primary HCC and an association between higher expression of selected factors and poorer patient survival. In the HAIC cohort, several DDR genes, including ATR, BRCA2, CDK7, MUS81, MUTYH, PARG, POLH, POLK and XPA, were significantly lower in the objective response group.

Conclusions

DDR components represent candidate biomarkers and therapeutic targets whose inhibition may enhance oxaliplatin efficacy in HCC.

Schlagwörter

Stichwörter der Autor:innen

CRISPR-Cas9 screenDNA repairhepatocellular carcinomaoxaliplatin

Autor:innen und Institutionen

  • Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

ORCID-Profile: Diyun Huang, Wenchao Wu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Young Talents Program of Sun Yat-sen University Cancer Center

Zitieren

APA

Ouyang, H., Huang, D., Wen, D., Huang, L., Wu, Z., Lai, Z., He, M., Wu, W., & Shi, M. (2026). Genome-Scale CRISPR Screens Reveal DNA Repair Dependencies That Sensitize Hepatocellular Carcinoma to Oxaliplatin. Cancers, 18(9), 1360. https://doi.org/10.3390/cancers18091360

Vancouver

Ouyang H, Huang D, Wen D, Huang L, Wu Z, Lai Z, et al. Genome-Scale CRISPR Screens Reveal DNA Repair Dependencies That Sensitize Hepatocellular Carcinoma to Oxaliplatin. Cancers. 2026;18(9):1360. doi:10.3390/cancers18091360

BibTeX
@article{Ouyang2026,
  author = {Ouyang, Hanyue and Huang, Diyun and Wen, Dongsheng and Huang, Lichang and Wu, Zichao and Lai, Zhicheng and He, Minke and Wu, Wenchao and Shi, Ming},
  title = {Genome-Scale CRISPR Screens Reveal DNA Repair Dependencies That Sensitize Hepatocellular Carcinoma to Oxaliplatin},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {9},
  pages = {1360},
  doi = {10.3390/cancers18091360}
}
Kostenlos starten →